These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Targeting mechanisms of hypertensive vascular disease with dual calcium channel and renin-angiotensin system blockade. Weir MR J Hum Hypertens; 2007 Oct; 21(10):770-9. PubMed ID: 17597800 [TBL] [Abstract][Full Text] [Related]
29. Peptides as targets for antihypertensive drug development. Hedner T; Sun X; Junggren IL; Pettersson A; Edvinsson L J Hypertens Suppl; 1992 Dec; 10(7):S121-32. PubMed ID: 1291647 [TBL] [Abstract][Full Text] [Related]
30. Targeting the renin-angiotensin-aldosterone system in atrial fibrillation: from pathophysiology to clinical trials. Boos CJ; Lip GY J Hum Hypertens; 2005 Nov; 19(11):855-9. PubMed ID: 16094406 [No Abstract] [Full Text] [Related]
31. Inhibiting the renin-angiotensin system: why and in which patients. Berra K; Miller NH J Am Acad Nurse Pract; 2009 Jan; 21(1):66-75. PubMed ID: 19125897 [TBL] [Abstract][Full Text] [Related]
32. Renin-angiotensin-aldosterone system blockade in high-risk hypertensive patients: current approaches and future trends. Gullapalli N; Bloch MJ; Basile J Ther Adv Cardiovasc Dis; 2010 Dec; 4(6):359-73. PubMed ID: 20965951 [TBL] [Abstract][Full Text] [Related]
33. [Comparison between AngII receptor antagonist and ACE inhibitor]. Fujimi K; Urata H Nihon Rinsho; 2001 May; 59(5):999-1003. PubMed ID: 11392005 [TBL] [Abstract][Full Text] [Related]
34. Aliskiren: a new inhibitor of renin-angiotensin aldosterone system activity. Dalla Vestra M; Simioni N; Masiero A Minerva Endocrinol; 2009 Dec; 34(4):333-8. PubMed ID: 20046162 [TBL] [Abstract][Full Text] [Related]
35. [Management of hypertensive patients with cardiovascular damage]. Tomiyama H; Takata Y; Yamashina A Nihon Rinsho; 2004 Mar; 62 Suppl 3():612-6. PubMed ID: 15171444 [No Abstract] [Full Text] [Related]
36. [Angiotensin II antagonists versus ACE inhibitors in the treatment of raised blood pressure]. Andersen RS; Christensen S Ugeskr Laeger; 2001 Dec; 163(50):7036-9. PubMed ID: 11794033 [TBL] [Abstract][Full Text] [Related]
37. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in hypertension due to primary aldosteronism: a case for exclusion. Bubbar CD; Blackburn DF; Wilson MP; Wilson TW Ann Pharmacother; 2007 Jan; 41(1):129-32. PubMed ID: 17179189 [TBL] [Abstract][Full Text] [Related]
38. [Hypertension in patients with diabetes]. Poulsen PL; Hansen KW; Gaede PH; Rossing P Ugeskr Laeger; 2009 Jun; 171(24):2031-4. PubMed ID: 19523370 [TBL] [Abstract][Full Text] [Related]
39. Effects of angiotensin inhibitors on renal injury and angiotensin receptor expression in early hypertensive nephrosclerosis. Nakaya H; Sasamura H; Kitamura Y; Amemiya T; Konishi K; Hayashi M; Saruta T Hypertens Res; 1999 Nov; 22(4):303-12. PubMed ID: 10580398 [TBL] [Abstract][Full Text] [Related]
40. Angiotensin converting enzyme inhibition and dihydropyridine calcium channel blockade in the treatment of left ventricular hypertrophy in arterial hypertension. Palmieri V; Devereux RB Minerva Cardioangiol; 2002 Jun; 50(3):169-74. PubMed ID: 12107398 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]